Apolipoprotein E4 (APOE4) and APOE4-driven transcriptional pathway (APOE4)

Apolipoprotein E4 (APOE4) is the most significant genetic risk factor for late-onset Alzheimer’s disease, with carriers of the ε4 allele exhibiting a significantly higher risk and earlier onset of the condition [1, 5]. Beyond its classical role in lipid transport and cholesterol metabolism, APOE4 is increasingly recognized as a transcriptional regulator that can translocate to the nucleus or trigger signaling cascades to modulate the expression of over 1,700 genes [2, 8, 19]. This "APOE4-driven transcriptional pathway" influences critical pathological processes, including amyloid-beta production, tau hyperphosphorylation, neuroinflammation, and mitochondrial dysfunction [1, 20, 21]. Therapeutic strategies targeting this pathway include small-molecule structure correctors like PH002 that revert APOE4 to a less toxic APOE3-like conformation, antisense oligonucleotides (ASOs) to silence APOE4 expression, and gene therapies such as LX1001 aimed at introducing the protective APOE2 isoform [12, 17, 26, 29]. Additionally, drugs like valiltramiprosate are being developed to block specific downstream signaling events or protein aggregations associated with the APOE4 phenotype [22, 33]. Understanding and modulating the APOE4-driven transcriptional landscape represents a promising frontier for precision medicine in neurodegenerative diseases [14, 19].

Other names

Apolipoprotein E epsilon 4APOE-ε4AD2LPGLDLCQ5

Structure correction of APOE4 to an APOE3-like conformation, inhibition of amyloid-beta oligomerization, gene replacement with APOE2, gene silencing of APOE4, and enhancement of ABCA1-mediated lipid efflux.